Table 3.
Outcomes of Mortality, Renal Recovery, and Comorbidities Measured at Discharge and 3-Month Follow-Up Stratified by Both Tenofovir Disoproxil Fumarate Exposure and Duration of Tenofovir Disoproxil Fumarate Use (n = 175)
| Duration of TDF use | |||||||
|---|---|---|---|---|---|---|---|
| TDF | Non-TDF | p | <6 Weeks | 6–24 Weeks | >24 Weeks | p | |
| 93 (53) | 82 (47) | 20 (22) | 25 (27) | 48 (51) | |||
| Mortality at discharge | |||||||
| Deceased, n (%) | 16 (17) | 10 (12) | .353 | 4 (20) | 5 (20) | 7 (15) | .787 |
| Fluid therapy alone, n (%) | 88 (95) | 80 (98) | .322 | 19 (95) | 25 (100) | 44 (92) | .324 |
| Deceased, n (%) | 13 (15) | 9 (11) | .499 | 3 (16) | 5 (20) | 5 (11) | .617 |
| Fluid and renal replacement therapy, n (%) | 5 (5) | 2 (2) | .322 | 1 (5) | 0 (0) | 4 (8) | .324 |
| Deceased, n (%) | 3 (60) | 1 (50) | .809 | 1 (100) | 0 (0) | 2 (50) | .361 |
| Duration of stay (days), median (IQR) | |||||||
| If survived | 9 (7–15) | 9 (7–14) | .722 | 8 (7–20) | 11 (7–15) | 9 (7–15) | .949 |
| If deceased | 10 (6–16) | 13 (9–16) | .286 | 11 (10–15) | 10 (7–37) | 6 (5–16) | .666 |
| Mortality after 3-month follow-up | |||||||
| Deceased, n (%) | 25 (27) | 22 (27) | .921 | 6 (30) | 8 (32) | 11 (23) | .665 |
| Duration to death (days), median (IQR) | |||||||
| Admission to death | 30 (13–40) | 64 (57–129) | .049 | 35 (30–40) | 28 (13–125) | 25 (13–88) | .783 |
| Discharge to death | 24 (18–30) | 52 (47–122) | .016 | 22 (18–25) | 23 (5–97) | 28 (6–30) | .895 |
| Renal parameters on discharge | |||||||
| Renal recovery among deceased, n (%) | |||||||
| Complete creatinine recovery | 3 (20) | 1 (10) | .504 | 0 (0) | 1 (25) | 2 (29) | .501 |
| Partial creatinine recovery | 7 (47) | 5 (50) | .870 | 2 (50) | 3 (75) | 2 (29) | .328 |
| Worsening creatinine | 5 (33) | 4 (40) | .734 | 2 (50) | 0 (0) | 3 (42) | .248 |
| Renal recovery among survivors, n (%) | |||||||
| Complete creatinine recovery | 37 (48) | 39 (54) | .456 | 9 (69) | 9 (47) | 19 (51) | .438 |
| Partial creatinine recovery | 32 (42) | 19 (26) | .051 | 4 (31) | 10 (53) | 18 (49) | .438 |
| Creatinine and eGFR (CKD-EPI) at death by renal recovery | |||||||
| By creatinine (μmol/l), median (IQR) | |||||||
| Deceased and complete recovery | 79 (78–83) | 92 (92–92) | .5 | — | 83 (83–83) | 79 (79–79) | .667 |
| Deceased and partial recovery | 283 (131–368) | 271 (139–513) | 1 | 326 (283–368) | 131 (116–147) | 574 (311–836) | .095 |
| Deceased and worsening creatinine | 572 (527–627) | 388 (366–577) | .413 | 577 (527–627) | — | 572 (227–852) | 1 |
| By eGFR (ml/min per 1.73 m2), median (IQR) | |||||||
| Deceased and complete recovery | 77 (76–78) | 63 (63–63) | .5 | — | 76 (76–76) | 78 (78–78) | .667 |
| Deceased and partial recovery | 13 (8–41) | 13 (5–38) | 1 | 10 (8–13) | 41 (33–48) | 6 (2–9) | .095 |
| Deceased and worsening creatinine | 4 (3–5) | 7 (7–12) | .413 | 4 (4–5) | — | 3 (2–18) | 1 |
| Renal parameters after 3-month follow-up | |||||||
| Renal recovery among survivors, n (%) | |||||||
| Complete creatinine recovery | 37 (61) | 40 (78) | .043 | 8 (62) | 7 (54) | 22 (63) | .849 |
| Partial creatinine recovery | 9 (15) | 2 (4) | .055 | 0 (0) | 2 (15) | 7 (20) | .221 |